Compare · INBS vs QDEL
INBS vs QDEL
Side-by-side comparison of Intelligent Bio Solutions Inc. (INBS) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. INBS focuses on Medical/Dental Instruments, while QDEL focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances.
- QDEL is the larger of the two at $700.5M, about 140.8x INBS ($5.0M).
- INBS has been more active in the news (5 items in the past 4 weeks vs 4 for QDEL).
- QDEL has more recent analyst coverage (19 ratings vs 0 for INBS).
- Company
- Intelligent Bio Solutions Inc.
- QuidelOrtho Corporation
- Price
- -
- -
- Market cap
- $5.0M
- $700.5M
- 1M return
- -
- -20.94%
- 1Y return
- -
- -51.55%
- Industry
- Medical/Dental Instruments
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 4
- Recent ratings
- 0
- 19
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest INBS
- Intelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Intelligent Bio Solutions Inc.
- Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth
- Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12
- SEC Form DEF 14A filed by Intelligent Bio Solutions Inc.
- SEC Form PRE 14A filed by Intelligent Bio Solutions Inc.
- Amendment: SEC Form 10-K/A filed by Intelligent Bio Solutions Inc.
- SEC Form 8-K filed by Intelligent Bio Solutions Inc.
- SEC Form EFFECT filed by Intelligent Bio Solutions Inc.
- SEC Form 424B3 filed by Intelligent Bio Solutions Inc.
Latest QDEL
- SEC Form SCHEDULE 13G filed by QuidelOrtho Corporation
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- QuidelOrtho Reports Third Quarter 2026 Financial Results
- Transforming Data Into Actionable Insights in the Lab
- QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
- SEC Form 4 filed by QuidelOrtho Corporation
- QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
- Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment